Is Mankind Pharma overvalued or undervalued?

As of 26 September 2025, Mankind Pharma's valuation grade has moved from very expensive to expensive, indicating a slight improvement in its perceived value but still suggesting it is on the higher end of the valuation spectrum. The company is currently assessed as overvalued, with a PE ratio of 54.02, a Price to Book Value of 7.15, and an EV to EBITDA ratio of 31.27, all of which are significantly higher than many of its peers.
In comparison, Sun Pharma has a PE ratio of 33.18 and an EV to EBITDA of 22.43, while Cipla stands out with a more attractive valuation at a PE of 22.45 and an EV to EBITDA of 15.77. Mankind's high valuation ratios, particularly its PEG ratio of 0.00, suggest that the market may be pricing in excessive growth expectations that may not materialize. Additionally, Mankind Pharma's stock has underperformed relative to the Sensex, with a year-to-date return of -13.96% compared to the Sensex's 2.93%, further reinforcing the view that the stock is overvalued.